ENDOLOGIX, INC. (NASDAQ:ELGX) Files An 8-K Entry into a Material Definitive Agreement

0
ENDOLOGIX, INC. (NASDAQ:ELGX) Files An 8-K Entry into a Material Definitive Agreement

ENDOLOGIX, INC. (NASDAQ:ELGX) Files An 8-K Entry into a Material Definitive Agreement
Item 1.01

On May 26, 2020, Endologix, Inc. (the “Company”) entered into a forbearance agreement (the “ABL Forbearance Agreement”) to Credit Agreement, dated as of August 9, 2018 (as amended, restated, supplemented or otherwise modified from time to time, the “Credit Agreement”), with the Lenders party thereto from time to time, and Deerfield ELGX Revolver, LLC, as agent for itself and the Lenders (collectively, the “ABL Forbearing Parties”). Additionally, on May 26, 2020, the Company entered into a forbearance agreement (the “Facility Forbearance Agreement” and, collectively with the ABL Forbearance Agreement, the “Forbearance Agreements”) to Amended and Restated Facility Agreement, dated as of August 9, 2018 (as amended, restated, supplemented or otherwise modified from time to time, the “Facility Agreement”), with the Lenders party thereto from time to time, and Deerfield Private Design Fund I.V., L.P. as agent for itself and the Lenders (collectively, the “Facility Forbearing Parties” and, collectively with the ABL Forbearing Parties, the “Forbearing Parties).

The Company informed the Forbearing Parties that it anticipated its Quarterly Report on Form 10-Q for the period ending March 31, 2020 would include a statement that there is substantial doubt regarding the Company’s ability to continue as a going concern within one year after the date of such financial statements and such statement would result in an event of default under each of the Credit Agreement and the Facility Agreement. to the Forbearance Agreements, subject to certain terms and conditions, the Forbearing Parties have agreed to forbear from exercising any rights or remedies arising from such event of default under the Credit Agreement or Facility Agreement, as applicable. As a condition to the Forbearance Agreements, the interest rate on all obligations under the Credit Agreement and the Facility Agreement, respectively, would increase by 2% per annum and the Company agreed to certain covenants.

The Forbearance Agreements will terminate on the earlier of June 15, 2020 or the occurrence of certain other conditions, including the occurrence of a separate event of default (the “Forbearance Termination Date”).

The foregoing descriptions of the ABL Forbearance Agreement and the Facility Forbearance Agreement are not complete and are qualified in their entirety by reference to the full text of the ABL Forbearance Agreement and of the Facility Forbearance Agreement, copies of which are filed herewith as Exhibit 10.1 and 10.2, respectively, and to this Current Report on Form 8-K and are incorporated herein by reference.

(d) Exhibits

10.1    Forbearance Agreement, dated as of May 26, 2020, to that certain Credit Agreement, dated as of August  9, 2018 (as amended, restated, supplemented or otherwise modified from time to time), by and among Endologix, Inc., the Lenders party thereto from time to time, and Deerfield ELGX Revolver, LLC
10.2    Forbearance Agreement, dated as of May 26, 2020, to that certain Amended and Restated Facility Agreement, dated as of August  9, 2018 (as amended, restated, supplemented or otherwise modified from time to time), by and among Endologix, Inc., the Lenders party thereto from time to time, and Deerfield Private Design Fund I.V., L.P.


ENDOLOGIX INC /DE/ Exhibit
EX-10.1 2 d937438dex101.htm EX-10.1 EX-10.1 Exhibit 10.1 EXECUTION VERSION FORBEARANCE AGREEMENT AND AMENDMENT TO CREDIT AGREEMENT This FORBEARANCE AGREEMENT (this “Agreement”),…
To view the full exhibit click here

About ENDOLOGIX, INC. (NASDAQ:ELGX)

Endologix, Inc. is engaged in developing, manufacturing, marketing and selling medical devices for the treatment of aortic disorders. The Company’s products are intended for the treatment of abdominal aortic aneurysms (AAA). The AAA products are built on one of two platforms, including traditional minimally invasive endovascular repair (EVAR) or endovascular sealing (EVAS), its solution for sealing the aneurysm sac while maintaining blood flow through two blood flow lumens. The EVAR products include the Endologix AFX Endovascular AAA System (AFX), the VELA Proximal Endograft (VELA) and the Endologix Powerlink with Intuitrak Delivery System (Intuitrak). The EVAS product is the Nellix EndoVascular Aneurysm Sealing System (Nellix EVAS System). Its EVAS product is the Nellix EndoVascular Aneurysm Sealing System (Nellix EVAS System). It offers accessories to facilitate the optimal delivery of its EVAR products, including compatible guidewires, snares, and catheter introducer sheaths.